|
|
|
Volumn 25, Issue 5, 2005, Pages
|
|
Bladder cancer: current optimal intravesical treatment.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
ANTINEOPLASTIC AGENT;
BCG VACCINE;
DOXORUBICIN;
DRUG DERIVATIVE;
EPIRUBICIN;
IMMUNOLOGICAL ADJUVANT;
MITOMYCIN;
THIOTEPA;
VALRUBICIN;
BLADDER TUMOR;
CYSTECTOMY;
DRUG ADMINISTRATION;
HUMAN;
INTRAVESICAL DRUG ADMINISTRATION;
METHODOLOGY;
NURSE ATTITUDE;
NURSING;
PATIENT SELECTION;
REVIEW;
RISK FACTOR;
SALVAGE THERAPY;
SURVIVAL RATE;
TREATMENT FAILURE;
TUMOR RECURRENCE;
UNITED STATES;
ADJUVANTS, IMMUNOLOGIC;
ADMINISTRATION, INTRAVESICAL;
ANTINEOPLASTIC AGENTS;
BCG VACCINE;
CYSTECTOMY;
DOXORUBICIN;
DRUG ADMINISTRATION SCHEDULE;
EPIRUBICIN;
HUMANS;
INTERFERON-ALPHA;
MITOMYCIN;
NEOPLASM RECURRENCE, LOCAL;
NURSE'S ROLE;
PATIENT SELECTION;
RISK FACTORS;
SALVAGE THERAPY;
SURVIVAL RATE;
THIOTEPA;
TREATMENT FAILURE;
UNITED STATES;
URINARY BLADDER NEOPLASMS;
|
|
EID: 33644846284
PISSN: 1053816X
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (28)
|
|
References (19)
|
